Cover Image
市場調查報告書

酪胺酸蛋白激酶JAK3:開發中產品分析

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 367828
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
酪胺酸蛋白激酶JAK3:開發中產品分析 Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 95 Pages
簡介

本報告提供以酪胺酸蛋白激酶JAK3為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪胺酸蛋白激酶JAK3 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Aclaris Therapeutics, Inc.
  • Advinus Therapeutics Ltd
  • Arrien Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Chipscreen Biosciences Ltd
  • Creabilis SA
  • F. Hoffmann-La Roche Ltd.
  • Ligand Pharmaceuticals, Inc.
  • MYOS RENS Technology Inc.
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • Principia Biopharma Inc.
  • Rigel Pharmaceuticals, Inc.
  • Theravance Biopharma, Inc.
  • Vectura Group Plc

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0801TDB

Summary

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 25 molecules. Out of which approximately 25 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 3, 12 and 5 respectively. Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Ulcerative Colitis, Alopecia, Atopic Dermatitis, Autoimmune Disorders, Psoriasis, Diffuse Large B-Cell Lymphoma, Inflammation, Vitiligo, Allergic Conjunctivitis, Androgenic Alopecia, Asthma, Auto Inflammatory Disease, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Mantle Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL), Respiratory Tract Inflammatory Disorders, Sarcopenia, Skin Inflammation, Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Waldenstrom Macroglobulinemia.

The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview
    • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    • Aclaris Therapeutics Inc
    • Advinus Therapeutics Ltd
    • Arrien Pharmaceuticals LLC
    • Astellas Pharma Inc
    • Bristol-Myers Squibb Company
    • Chipscreen Biosciences Ltd
    • Clevexel Pharma SAS
    • F. Hoffmann-La Roche Ltd
    • Japan Tobacco Inc
    • Merck & Co Inc
    • MYOS RENS Technology Inc
    • Pfizer Inc
    • Portola Pharmaceuticals Inc
    • Simcere Pharmaceutical Group
    • Theravance Biopharma Inc
    • Vectura Group Plc
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles
    • ARN-4079 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-50001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-50002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-50003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerdulatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-510 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-944X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVXL-0074 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JTE-052 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OST-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peficitinib hydrobromide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06651600 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNQ-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Autoimmune Diseases and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Janus Kinase 3 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SNA-125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-1473 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-3504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tofacitinib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VR-588 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones
    • Featured News & Press Releases
      • May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association
      • May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma
      • May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
      • May 03, 2017: Pfizer Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Active Psoriatic Arthritis
      • May 03, 2017: Phase 3 Octave Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal Of Medicine
      • Mar 27, 2017: XELJANZ Receives Marketing Authorisation In The European Union For The Treatment Of Moderate To Severe Active Rheumatoid Arthritis
      • Mar 15, 2017: Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
      • Mar 13, 2017: European League Against Rheumatism (EULAR) Includes Janus Kinase (JAK) Inhibitors in Updated Recommendations for the Management of RA
      • Mar 04, 2017: Pfizer to Present Psoriatic Arthritis Data at American Academy of Dermatology Annual Meeting
      • Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
      • Feb 16, 2017: Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ (tofacitinib citrate) Compared to Humira (adalimumab)
      • Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
      • Jan 27, 2017: Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis
      • Dec 07, 2016: Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis
      • Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Aclaris Therapeutics Inc, H1 2017
  • Pipeline by Advinus Therapeutics Ltd, H1 2017
  • Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Pipeline by Astellas Pharma Inc, H1 2017
  • Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Pipeline by Clevexel Pharma SAS, H1 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Pipeline by Japan Tobacco Inc, H1 2017
  • Pipeline by Merck & Co Inc, H1 2017
  • Pipeline by MYOS RENS Technology Inc, H1 2017
  • Pipeline by Pfizer Inc, H1 2017
  • Pipeline by Portola Pharmaceuticals Inc, H1 2017
  • Pipeline by Simcere Pharmaceutical Group, H1 2017
  • Pipeline by Theravance Biopharma Inc, H1 2017
  • Pipeline by Vectura Group Plc, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
Back to Top